ID   KBM-3/DOX
AC   CVCL_H688
DR   cancercelllines; CVCL_H688
DR   ChEMBL-Cells; CHEMBL3307838
DR   ChEMBL-Targets; CHEMBL613994
DR   PubChem_Cell_line; CVCL_H688
DR   Wikidata; Q54899584
RX   PubMed=1995877;
CC   Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Adriamycin).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
DI   NCIt; C7463; Acute myelomonocytic leukemia
DI   ORDO; Orphanet_517; Acute myelomonocytic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_A425 ! KBM-3
SX   Female
AG   32Y
CA   Cancer cell line
DT   Created: 11-02-13; Last updated: 05-10-23; Version: 15
//
RX   PubMed=1995877; DOI=10.1021/jm00106a013;
RA   Farquhar D., Newman R.A., Zuckerman J.E., Andersson B.S.;
RT   "Doxorubicin analogues incorporating chemically reactive
RT   substituents.";
RL   J. Med. Chem. 34:561-564(1991).
//